Ceftazidime: A Third-Generation Cephalosporin for Pseudomonas and β-Lactamase Resistance

Executive Summary: Ceftazidime is a third-generation cephalosporin with broad-spectrum activity against Gram-negative pathogens, most notably Pseudomonas aeruginosa (APExBIO product page). It is highly resistant to β-lactamase hydrolysis, retaining efficacy against β-lactamase-producing Enterobacteriaceae (Chen et al., 2025). Ceftazidime is less active against Gram-positive Staphylococcus aureus compared to earlier-generation cephalosporins. Recommended research doses range from 3–6 g/day divided into 2–4 administrations, with high solubility in DMSO (≥21.25 mg/mL) and stability below -20°C. It acts by inhibiting bacterial cell wall synthesis, making it indispensable in studies of resistant respiratory infections and multidrug resistance transmission dynamics.

Biological Rationale

Ceftazidime is a third-generation cephalosporin antibiotic classified under β-lactam agents. It is structurally optimized to target Gram-negative aerobic bacteria, especially Pseudomonas aeruginosa, and is less susceptible to hydrolysis by common β-lactamases (APExBIO). This property is crucial, as β-lactamase production is a primary resistance mechanism in Enterobacteriaceae and Pseudomonas species (Chen et al., 2025). During the COVID-19 pandemic, increased antibiotic usage and complex infections have fueled the spread of multidrug-resistant bacteria, reinforcing the need for robust agents like ceftazidime. Its ability to inhibit cell wall synthesis via penicillin-binding proteins (PBPs) underpins its bactericidal action (Naloxonesmallmol article). Ceftazidime's molecular weight is 546.58 g/mol, chemical formula C₂₂H₂₂N₆O₇S₂, and it is provided as a solid for research applications.

Mechanism of Action of Ceftazidime

Ceftazidime exerts its antibacterial effect by binding to and inhibiting penicillin-binding proteins (PBPs) involved in peptidoglycan cross-linking. This inhibition disrupts bacterial cell wall synthesis, leading to cell lysis and death (Azosemidecompound article). Its high resistance to hydrolysis by β-lactamases, including extended-spectrum β-lactamases (ESBLs), enables activity against many multidrug-resistant Gram-negative organisms. Ceftazidime also demonstrates efficacy against Pseudomonas cepacia, P. alcaligenes, and P. putida. However, decreased efficacy is observed against Gram-positive species such as Staphylococcus aureus, where first- and second-generation cephalosporins are more potent (APExBIO).

Evidence & Benchmarks

• Ceftazidime exhibits broad in vitro activity against both Gram-positive and Gram-negative aerobic bacteria, with highest efficacy against Pseudomonas aeruginosa (APExBIO).
• Resistance to β-lactamase hydrolysis is confirmed, making ceftazidime effective against β-lactamase-producing Enterobacteriaceae strains (Chen et al., 2025).
• In a study of 54 carbapenem-resistant Enterobacter cloacae isolates, ceftazidime/avibactam resistance rates were significantly higher in carbapenemase-encoding gene (CEG)-positive isolates (P<0.05), highlighting the challenge of resistance evolution (Chen et al., 2025).
• Recommended research and clinical dosing is 3–6 g/day, divided into 2–4 doses, for respiratory infections such as pneumonia and bronchitis (APExBIO).
• Ceftazidime is soluble at ≥21.25 mg/mL in DMSO, but insoluble in water and ethanol; stock solutions are stable at -20°C (APExBIO).

Applications, Limits & Misconceptions

Ceftazidime is widely applied in research and clinical settings for the treatment of Gram-negative bacterial infections, especially those caused by Pseudomonas aeruginosa. It is also used in experimental models to study resistance dynamics and cell viability assays, where its broad spectrum and β-lactamase stability are critical advantages (Tcephydrochloride article). This article extends the scenario-driven guidance of the above resource by focusing on multidrug-resistant transmission benchmarks post-pandemic.

Common Pitfalls or Misconceptions

• Not effective against methicillin-resistant Staphylococcus aureus (MRSA): Ceftazidime has low activity against MRSA and is not indicated for these infections (APExBIO).
• Resistance can develop in some Pseudomonas strains: Prolonged or inappropriate use may select for resistant subpopulations, limiting efficacy (Chen et al., 2025).
• Incorrect solvent use: Ceftazidime is insoluble in water and ethanol; dissolution should be in DMSO at recommended concentrations (APExBIO).
• Instability at higher temperatures: Stock solutions lose activity if not stored below -20°C (APExBIO).
• Not universally effective against all Gram-negatives: Some carbapenemase-encoding gene-positive Enterobacteriaceae exhibit multi-drug resistance, requiring combinatorial or alternative therapies (Chen et al., 2025).

Workflow Integration & Parameters

For experimental use, ceftazidime (SKU B3539) from APExBIO is dispensed as a solid. It is reconstituted in DMSO at ≥21.25 mg/mL. For microbiological assays, choose concentrations and dosing intervals based on the targeted bacterial species and resistance profile. Stock solutions must be stored at -20°C. Solutions should be used promptly to prevent hydrolysis and maintain activity.

In cell-based infection models, ceftazidime is frequently employed for selective pressure or as a comparator in antimicrobial resistance studies (Tcephydrochloride scenario article). This article updates previous guidance by incorporating new resistance surveillance data from Chen et al. (2025), highlighting the importance of precise dosing and handling parameters for reproducible results.

Conclusion & Outlook

Ceftazidime remains a cornerstone for Gram-negative infection research and treatment, especially in the face of rising multidrug-resistant pathogens. Its β-lactamase resistance, broad spectrum, and suitability for diverse experimental workflows reinforce its value. However, resistance mechanisms continue to evolve, necessitating ongoing surveillance and judicious use. For further mechanistic details and advanced applications, see the related article 'Ceftazidime: Advanced Insights into β-Lactamase Resistance', which this dossier complements by providing updated clinical-genomic context and workflow guidance.